Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Hemostemix Closes $480,000 Private Placement at $0.12 per Share

By The Northwire Desk — AI Analysis Dec 31, 2025 · 14:39 HEM · 0.085 Hemostemix Inc.
HEM · Price

Executive Summary

  • Hemostemix Inc. closed a non‑brokered private placement raising CDN $480,000 by issuing 4,000,000 common shares at $0.12 per share.
  • Proceeds will be used for general working capital, specifically to advance regulatory, clinical and commercialization initiatives for the ACP‑01 (VesCell) autologous angiogenic cell therapy platform.
  • All issued securities are subject to a statutory hold period and the placement remains pending final acceptance by the TSX Venture Exchange.

Key Details

  • Gross proceeds: CDN $480,000.
  • Shares issued: 4,000,000 common shares.
  • Price per share: $0.12 CAD.
  • Placement type: Non‑brokered private placement (non‑institutional investors).
  • Use of proceeds: General working capital; funding regulatory filings, clinical trial activities, and commercialization efforts for ACP‑01 (VesCell).
  • Statutory hold period: Shares subject to hold in accordance with securities laws and TSXV policies.
  • TSXV acceptance: Placement pending final acceptance by the Toronto Stock Exchange Venture Board.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Hemostemix Inc.

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Jun 17, 2026 · 17:23

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

Financings Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory Dec 31, 2025 · 18:13

Hemostemix closes $480,000 financing

Financings